Quinoline RAGE Modulators Targeting Intracellular Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents are inadequate for effectively modulating the activity of the receptor for advanced glycation end products (RAGE), which is central to the pathogenesis of diabetes complications, obesity, inflammation, cancer, and neurodegeneration, necessitating the development of novel compounds that can inhibit RAGE activity.
Innovation Solution
Development of quinoline compounds that modulate the interaction of RAGE and its ligands, particularly targeting the intracellular domain, to inhibit RAGE activity and treat associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to modulate RAGE activity, then treatment of RAGE-associated diseases is attempted, but the therapeutic effect is inadequate
Solution Approach 1:
The patent modifies the chemical structure parameters of existing RAGE modulators by introducing specific quinoline core structures with varying substituents (R1, R2, R3, R4, R5, R6) and fusion patterns. These structural parameter changes create a series of compounds with optimized binding affinity and selectivity for RAGE, thereby improving therapeutic efficacy across multiple disease indications including diabetes complications, inflammation, cancer, and neurodegeneration.
2Manufacturing precision
If quinoline compounds are designed to target intracellular domain of RAGE, then specificity of RAGE modulation is improved, but complexity of drug design increases
Solution Approach 1:
The quinoline compound structure is segmented into distinct functional regions: the core quinoline system (positions 1-8), substituent positions (R1-R6) that provide specific interactions with RAGE, and optional fusion ring systems. This segmentation allows systematic optimization of each region independently to achieve high specificity for the intracellular domain of RAGE while managing molecular complexity through modular design.
Solution Approach 2:
The patent employs composite molecular structures combining the quinoline core with various heterocyclic fusion rings (such as benzofuran, indole, or pyridine fused systems) and diverse substituents. This composite approach creates molecules with multiple interaction points that specifically recognize and bind to the intracellular domain of RAGE, achieving high modulation specificity despite increased structural complexity.
3Object-affected harmful factors
If RAGE activity is inhibited to treat diseases, then disease progression is reduced, but potential side effects from broad RAGE inhibition may occur
Solution Approach 1:
The quinoline compounds act as intermediary molecules that selectively bind to the intracellular domain of RAGE (ctRAGE) and modulate its interaction with downstream signaling partners such as DIAPH1. By targeting this specific interface, the compounds inhibit pathological RAGE signaling in diseases while potentially preserving essential physiological functions, thereby reducing side effects compared to broad RAGE inhibition approaches.
Data Source
AI summary
Quinoline compounds are disclosed that have a formula represented by the following; and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as compositions, e g., pharmaceutical compositions, or as dosage forms, e.g., pharmaceutical dosage forms, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease, COVID-19 complications, and other diseases related to RAGE activity.